364 related articles for article (PubMed ID: 22903686)
1. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
3. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
4. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
Hu ZY; Xiao H; Xiao M; Tang Y; Sun J; Xie ZM; Ouyang Q
Clin Breast Cancer; 2018 Oct; 18(5):e1149-e1163. PubMed ID: 29885789
[TBL] [Abstract][Full Text] [Related]
5. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
7. Receptor changes in metachronous breast tumors--our experience of 10 years.
Bhullar JS; Unawane A; Subhas G; Poonawala H; Dubay L; Ferguson L; Goriel Y; Jacobs MJ; Kolachalam RB; Silapaswan S; Mittal VK
Am J Surg; 2012 Mar; 203(3):405-9; discussion 409. PubMed ID: 22206855
[TBL] [Abstract][Full Text] [Related]
8. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
9. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
[TBL] [Abstract][Full Text] [Related]
10. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
Xing P; Li J; Jin F
Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
[TBL] [Abstract][Full Text] [Related]
11. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
12. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of triple negative breast cancers.
Gierach GL; Burke A; Anderson WF
Breast Dis; 2010; 32(1-2):5-24. PubMed ID: 21965309
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.
Runnak MA; Hazha MA; Hemin HA; Wasan AA; Rekawt RM; Michael HD
BMC Womens Health; 2012 Jun; 12():16. PubMed ID: 22727195
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
17. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
Bessonova L; Taylor TH; Mehta RS; Zell JA; Anton-Culver H
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):389-96. PubMed ID: 21217087
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
19. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
Neta G; Anderson WF; Gilbert E; Berrington A
Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
[TBL] [Abstract][Full Text] [Related]
20. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
